The long-term efficacy of intra-cervical lymphatic immunotherapy on adults with allergic rhinitis: A randomized controlled study

被引:2
作者
Qin, Yang [1 ]
Huang, Weijun [2 ]
Zheng, Rui [3 ]
Wang, Qixing [4 ]
Yu, Qingqing [2 ]
Li, Yin [2 ]
Wang, Kai [2 ]
Tang, Jun [1 ,2 ,5 ]
机构
[1] Guangdong Med Univ, Clin Med Coll 1, Zhanjiang, Peoples R China
[2] First Peoples Hosp Foshan, Dept Otolaryngol, 81 Lingnan Rd, Foshan 538000, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Otolaryngol, Guangzhou, Peoples R China
[4] Zunyi Med Univ, Zhu Hai Campus, Zhuhai, Peoples R China
[5] Guangdong Med Univ, 2 Wenming East Rd, Zhanjiang 524023, Peoples R China
基金
中国国家自然科学基金;
关键词
allergens; allergic rhinitis; immunotherapy; INTRALYMPHATIC IMMUNOTHERAPY; YOUNG-ADULTS; RHINOCONJUNCTIVITIS; ASTHMA;
D O I
10.1002/clt2.12341
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: The efficacy and safety of the novel immunotherapy method, intra-cervical lymphatic immunotherapy (ICLIT), need to be investigated. Comparing it with subcutaneous immunotherapy (SCIT), we clarified the long-term efficacy and safety of intra-cervical lymphatic immunotherapy on allergic rhinitis (AR), and investigated the improvement of clinical efficacy of the booster injection at 1 year after ICLIT treatment. Methods: Ninety adult patients with dust mite allergy were randomly divided into 3 groups: 30 in the SCIT group, 30 in the ILCLIT group, and 30 in ICLIT booster group. Changes in total symptom score (TSS), nasal symptom score (TNSS), ocular symptom score (TOSS) and total medication score (TMS) were evaluated in the three groups. Adverse reactions were recorded, and serum dust mite specific IgE (sIgE) and specific IgG4 were assessed in the ICLIT group and ICLIT booster group. Results: TSS, TNSS, TOSS, and TMS scores were significantly lower in the three groups at 36 months after treatment (p < 0. 05). And at 36 months the ICLIT-booster group showed results similar to SCIT and superior to ICLIT (p < 0. 05). Serum specific IgE decreased in all three groups at 12 and 36 months after treatment, p < 0.01. The ICLIT group and the ICLIT booster group showed a significant increase in sIgG4, p < 0.01. None of the patients in the three groups had any serious systemic adverse effects during the 3-year follow-up. Conclusion: The ICLIT treatment is effective and safe on AR. One booster injection of allergens at 1 year can greatly improve its long-term efficacy.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Clinical course of rhinitis and changes in vivo and in vitro of allergic parameters in elderly patients: a long-term follow-up study
    Di Lorenzo, Gabriele
    Leto-Barone, Maria Stefania
    La Piana, Simona
    Ditta, Vito
    Di Fede, Gaetana
    Rini, Giovam Battista
    CLINICAL AND EXPERIMENTAL MEDICINE, 2013, 13 (01) : 67 - 73
  • [42] Efficacy and safety of levocetirizine in improving symptoms and health-related quality of life in US adults with seasonal allergic rhinitis: a randomized, placebo-controlled study
    Segall, Nathan
    Gawchik, Sandra
    Georges, George
    Haeusler, Jean-Marc C.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2010, 104 (03) : 259 - 267
  • [43] Long-term safety of subcutaneous immunotherapy with TO-204 in Japanese patients with house dust mite-induced allergic rhinitis and allergic bronchial asthma: Multicenter, open label clinical trial
    Fujisawa, Takao
    Shimoda, Terufumi
    Masuyama, Keisuke
    Okubo, Kimihiro
    Honda, Kohei
    Okano, Mitsuhiro
    Katsunuma, Toshio
    Urisu, Atsuo
    Kondo, Yasuto
    Odajima, Hiroshi
    Kurihara, Kazuyuki
    Nagata, Makoto
    Taniguchi, Masami
    Taniuchi, Shoichiro
    Doi, Satoru
    Matsumoto, Tomoshige
    Hashimoto, Shoji
    Tanaka, Akihiko
    Natsui, Kensuke
    Abe, Nahoko
    Ozaki, Hideki
    ALLERGOLOGY INTERNATIONAL, 2018, 67 (03) : 347 - 356
  • [44] Proof of Efficacy Study to Evaluate an Ayurvedic Formulation in the Treatment of Allergic Rhinitis: An Open Label Randomized Controlled Clinical Trial
    Prakash, Vaidya B.
    Rao, Yashwant K.
    Prakash, Shikha
    Sati, Sneha T.
    Mohapatra, Ankita
    Negi, Neha
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (10)
  • [45] Efficacy of intramuscular BCG polysaccharide nucleotide on mild to moderate bronchial asthma accompanied with allergic rhinitis: a randomized, double blind, placebo-controlled study
    Li, J
    Luo, DF
    Li, SY
    Sun, BQ
    Zhong, NS
    CHINESE MEDICAL JOURNAL, 2005, 118 (19) : 1595 - 1603
  • [46] Efficacy and safety of two Ayurvedic dosage forms for allergic rhinitis: Study protocol for an open-label randomized controlled trial
    Dahanayake, Jeevani Maheshika
    Perera, Pathirage Kamal
    Galappaththy, Priyadarshani
    Samaranayake, Dulani
    TRIALS, 2020, 21 (01)
  • [47] Efficacy and safety of two Ayurvedic dosage forms for allergic rhinitis: Study protocol for an open-label randomized controlled trial
    Jeevani Maheshika Dahanayake
    Pathirage Kamal Perera
    Priyadarshani Galappaththy
    Dulani Samaranayake
    Trials, 21
  • [48] Randomized double-blind placebo-controlled crossover study of efficacy of pollen blocker cream for perennial allergic rhinitis
    Li, Yanqing
    Wang, Dehui
    Liu, Quan
    Liu, Juan
    AMERICAN JOURNAL OF RHINOLOGY & ALLERGY, 2013, 27 (04) : 299 - 303
  • [49] Relationship between serum inhibitory activity for IgE and efficacy of Artemisia pollen subcutaneous immunotherapy for allergic rhinitis: a preliminary self-controlled study
    Wenping Wang
    Jinshu Yin
    Xueyan Wang
    Tingting Ma
    Tianfei Lan
    Qingkun Song
    Yifan Guo
    Allergy, Asthma & Clinical Immunology, 16
  • [50] Short-term influence of Immufen™ on mild allergic rhinitis: a randomized, double-blind, placebo-controlled study
    Mamatha, K.
    Aryan, Manu Kanjoormana
    Prabhakaran, Prathibha
    Mulakal, Johannah Natinga
    Das, S. Syam
    Krishnakumar, Im
    Panicker, Sreejith Parameswara
    FRONTIERS IN ALLERGY, 2024, 5